CIK 0001649094
PCVX Vaxcyte, Inc.
Insider trading from SEC Form 4. Last filing Dec 18, 2024.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
1
with a Form 4 at this company
Signals
Open-market buys and sells at Vaxcyte, Inc., scored.
No scored open-market trades yet. Grants, exercises and other rows are below.
Congressional trades
7 trades in PCVX disclosed by members of Congress under the STOCK Act. All congressional trades.
| Member | Type | Asset | Amount | Traded | Filed |
|---|---|---|---|---|---|
| Gilbert Ray Cisneros, Jr. House · D-CA | Purchase | PCVX Vaxcyte, Inc. - Common Stock | $1,001 to $15k | Jul 16, 2026 | 50 days after the trade |
| Gilbert Ray Cisneros, Jr. House · D-CA | Purchase | PCVX Vaxcyte, Inc. - Common Stock | $1,001 to $15k | May 13, 2026 | 26 days after the trade |
| Gilbert Ray Cisneros, Jr. House · D-CA | Purchase | PCVX Vaxcyte, Inc. - Common Stock | $1,001 to $15k | May 12, 2026 | 27 days after the trade |
| Gilbert Ray Cisneros, Jr. House · D-CA | Purchase | PCVX Vaxcyte, Inc. - Common Stock | $1,001 to $15k | Apr 14, 2025 | 22 days after the trade |
| Gilbert Ray Cisneros, Jr. House · D-CA | Purchase | PCVX Vaxcyte, Inc. - Common Stock | $1,001 to $15k | Apr 15, 2025 | 21 days after the trade |
| Gilbert Ray Cisneros, Jr. House · D-CA | Purchase | PCVX Vaxcyte, Inc. - Common Stock | $1,001 to $15k | Apr 28, 2025 | 8 days after the trade |
| Jefferson Shreve House · R-IN | Sale | PCVX Vaxcyte, Inc. - Common Stock | $15k to $50k | Mar 5, 2025 | 37 days after the trade |
Transactions
The last 3 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 16, 2024 | Cowan Elvia SVP, FINANCE | MOption exercise Common Stock | +7,716 | $25.92 | $200k | 19,294 | Dec 18, 2024 |
| Dec 16, 2024 | Cowan Elvia SVP, FINANCE | MOption exercise Stock Option (right to buy)derivative | -7,716 | $0.00 | $0 | 106,284 | Dec 18, 2024 |
| Nov 7, 2024 | Cowan Elvia SVP, FINANCE | AGrant or award Performance Stock Option (right to buy)derivative | +11,900 | $0.00 | $0 | 11,900 | Nov 8, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.